Index by author

November 01, 1993; Volume 60,Issue 6

  1. Bakst, Alan

    1. Hepatic toxicity of antirheumatic drugs
      Eric P. Brass, MD, PhD
      Cleveland Clinic Journal of Medicine November 1993, 60 (6) 466-472;

      Drug treatment of rheumatic diseases is associated with a small but well-documented risk of hepatotoxicity. Recognizing the clinical syndromes associated with liver injury by these agents facilitates the minimization of morbidity from this complication.

  2. Barnes, David S.

    1. Management of variceal bleeding in the 1990s
      J. Michael Henderson, MB, CHB, William D. Carey, MD, David P. Vogt, MD, David S. Barnes, MD, Margaret G. Zelch, MD and Cathy Blake, MSN, RN
      Cleveland Clinic Journal of Medicine November 1993, 60 (6) 431-438;

      Therapeutic options now include pharmacologic reduction of portal hypertension, endoscopic obliteration of varices, placement of decompressive shunts, and liver transplantation.

  3. Blake, Cathy

    1. Management of variceal bleeding in the 1990s
      J. Michael Henderson, MB, CHB, William D. Carey, MD, David P. Vogt, MD, David S. Barnes, MD, Margaret G. Zelch, MD and Cathy Blake, MSN, RN
      Cleveland Clinic Journal of Medicine November 1993, 60 (6) 431-438;

      Therapeutic options now include pharmacologic reduction of portal hypertension, endoscopic obliteration of varices, placement of decompressive shunts, and liver transplantation.

  4. Boskovich, Steven A.

    1. Systemic diseases associated with intermediate uveitis
      Steven A. Boskovich, MD, Careen Y. Lowder, MD, PhD, David M. Meisler, MD and Froncie A. Gutman, MD
      Cleveland Clinic Journal of Medicine November 1993, 60 (6) 460-465;

      Multiple sclerosis, inflammatory bowel disease, thyroid abnormalities, and possible Epstein-Barr virus infection were among the findings in 26 of 83 intermediate uveitis patients.

  5. Brass, Eric P.

    1. Hepatic toxicity of antirheumatic drugs
      Eric P. Brass, MD, PhD
      Cleveland Clinic Journal of Medicine November 1993, 60 (6) 466-472;

      Drug treatment of rheumatic diseases is associated with a small but well-documented risk of hepatotoxicity. Recognizing the clinical syndromes associated with liver injury by these agents facilitates the minimization of morbidity from this complication.

Back to top

In this issue